Efficacy and Safety of Lisdexamfetamine Versus Topiramate Versus Naltrexone/Bupropion in Individuals With Binge Eating Disorder: A Network Meta‐Analysis
European Eating Disorders Review · 2026-03 · 34 (2) · 334-346
DOI: 10.1002/erv.70035 ↗At a glance
Metaanalyse in European Eating Disorders Review, published online on 2025-09-22. Written by Tamer Hodrob and 5 co-authors. Institution: Faculty of Medicine, Al-Quds University, East Jerusalem, Palestine. Major MEDLINE topics: Naltrexone, Lisdexamfetamine Dimesylate, Topiramate, Binge-Eating Disorder. Cited 2 times so far (Crossref); 49 references. The full text is freely available (open access, CC BY 4.0).
Abstract (original language)
Objective
To compare the efficacy and safety of lisdexamfetamine, topiramate, and naltrexone/bupropion for treating binge eating disorder (BED) using network meta‐analysis.
Method
We systematically searched PubMed, Scopus, ClinicalTrials.gov, and Cochrane Central up to February 2025 for randomized controlled trials evaluating these medications versus placebo in adults with BED. Primary outcomes were changes in binge eating frequency and body weight; secondary outcomes included serious adverse events, discontinuation rates, and common side effects. A frequentist random‐effects network meta‐analysis was performed.
Results
Twelve trials ( n = 1988) met inclusion criteria. Both lisdexamfetamine (MD −1.61, 95% CI: −2.41 to −0.81) and topiramate (MD −1.63, 95% CI: −2.53 to −0.74) significantly reduced binge eating frequency versus placebo, with comparable efficacy. Topiramate produced the greatest weight loss (MD −5.5 kg), followed by lisdexamfetamine (−4.6 kg). Naltrexone/bupropion did not significantly reduce binge frequency (MD −2.07, 95% CI: −4.45 to 0.31). Lisdexamfetamine was associated with higher risks of dry mouth and gastrointestinal events. No significant increase in serious adverse events was observed for any medication.
Conclusions
Topiramate and lisdexamfetamine are effective for reducing binge episodes and weight in BED. Naltrexone/bupropion showed modest weight effects but lacked clear efficacy for binge reduction. These findings support topiramate and lisdexamfetamine as primary pharmacologic options for BED.
Subjects
MeSH terms (MEDLINE)
Author keywords
Substances
Authors and institutions
- Faculty of Medicine, Al-Quds University, East Jerusalem, Palestine.
- Department of Medical Laboratory Sciences, Al-Aqsa University, Gaza, Palestine.
- Deaconess Health System, Evansville, Indiana, USA.
ORCID profiles: Tamer Hodrob, Celina R Andonie, Hazem Ayesh
Cite
APA
Hodrob, T., Ismail, I., Abusalameh, A., Andonie, C. R., Ayesh, O., & Ayesh, H. (2026). Efficacy and Safety of Lisdexamfetamine Versus Topiramate Versus Naltrexone/Bupropion in Individuals With Binge Eating Disorder: A Network Meta‐Analysis. European Eating Disorders Review, 34(2), 334-346. https://doi.org/10.1002/erv.70035
Vancouver
Hodrob T, Ismail I, Abusalameh A, Andonie CR, Ayesh O, Ayesh H. Efficacy and Safety of Lisdexamfetamine Versus Topiramate Versus Naltrexone/Bupropion in Individuals With Binge Eating Disorder: A Network Meta‐Analysis. European Eating Disorders Review. 2026;34(2):334-346. doi:10.1002/erv.70035
BibTeX
@article{Hodrob2026,
author = {Hodrob, Tamer and Ismail, Ibrahim and Abusalameh, Alaaeddin and Andonie, Celina R and Ayesh, Omar and Ayesh, Hazem},
title = {Efficacy and Safety of Lisdexamfetamine Versus Topiramate Versus Naltrexone/Bupropion in Individuals With Binge Eating Disorder: A Network Meta‐Analysis},
journal = {European Eating Disorders Review},
year = {2026},
volume = {34},
number = {2},
pages = {334--346},
doi = {10.1002/erv.70035}
}
EUVIMED